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Reducing the rate and duration of Re-
ADMISsions among patients with unipolar
disorder and bipolar disorder using
smartphone-based monitoring and
treatment – the RADMIS trials: study
protocol for two randomized controlled trials
Maria Faurholt-Jepsen1,2*, Mads Frost3, Klaus Martiny1,2, Nanna Tuxen1,2, Nicole Rosenberg1,2, Jonas Busk4,
Ole Winther4, Jakob Eyvind Bardram4,5 and Lars Vedel Kessing1,2
Abstract
Background: Unipolar and bipolar disorder combined account for nearly half of all morbidity and mortality due to
mental and substance use disorders, and burden society with the highest health care costs of all psychiatric and
neurological disorders. Among these, costs due to psychiatric hospitalization are a major burden. Smartphones comprise
an innovative and unique platform for the monitoring and treatment of depression and mania. No prior trial has
investigated whether the use of a smartphone-based system can prevent re-admission among patients discharged from
hospital. The present RADMIS trials aim to investigate whether using a smartphone-based monitoring and treatment
system, including an integrated clinical feedback loop, reduces the rate and duration of re-admissions more than standard
treatment in unipolar disorder and bipolar disorder.
Methods: The RADMIS trials use a randomized controlled, single-blind, parallel-group design. Patients with unipolar
disorder and patients with bipolar disorder are invited to participate in each trial when discharged from psychiatric
hospitals in The Capital Region of Denmark following an affective episode and randomized to either (1) a smartphone-
based monitoring system including (a) an integrated feedback loop between patients and clinicians and (b) context-aware
cognitive behavioral therapy (CBT) modules (intervention group) or (2) standard treatment (control group) for a 6-month
trial period. The trial started in May 2017. The outcomes are (1) number and duration of re-admissions (primary), (2)
severity of depressive and manic (only for patients with bipolar disorder) symptoms; psychosocial functioning; number of
affective episodes (secondary), and (3) perceived stress, quality of life, self-rated depressive symptoms, self-rated manic
symptoms (only for patients with bipolar disorder), recovery, empowerment, adherence to medication, wellbeing,
ruminations, worrying, and satisfaction (tertiary). A total of 400 patients (200 patients with unipolar disorder and 200
patients with bipolar disorder) will be included in the RADMIS trials.
(Continued on next page)
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Discussion: If the smartphone-based monitoring system proves effective in reducing the rate and duration of re-
admissions, there will be basis for using a system of this kind in the treatment of unipolar and bipolar disorder in general
and on a larger scale.
Trial registration: ClinicalTrials.gov, ID: NCT03033420. Registered 13 January 2017. Ethical approval has been obtained.
Background
Unipolar disorder and bipolar disorder are common men-
tal diseases with a lifetime prevalence of 15–20% and 1–
2%, respectively [1, 2]. Unipolar disorder and bipolar dis-
order combined account for nearly half of all morbidity
and mortality due to mental and substance use disorders
[3] and burden society with the highest health care costs
of all psychiatric and neurological disorders [4].
Although psychiatric treatment internationally, and in
Denmark, has shifted more from inpatient treatment to
outpatient treatment during recent decades, costs due to
psychiatric hospitalization are still a major burden com-
prising two thirds of all direct costs in the five Regions of
Denmark [5]. Patients with affective disorders are more
frequently hospitalized than any other patient group,
counting more than 10,800 patients in 2013 among the en-
tire Danish population of 5.4 million people, and 20% of all
psychiatric hospitalizations in Denmark [6]. The cost of
these hospitalizations alone is estimated to be DKK648
million (approximately €8.7 million) per year in Denmark
(10,800 hospitalizations with a mean of 20 days’ stay for a
cost of 3000 DKK/day (€400)). The discharge period after
hospitalization is a high-risk period with a more than 300
times increased risk of suicide during the first week [7] and
a high risk of re-admission [8, 9]. Patients are often afraid
of leaving the hospital, feeling alone with the prospect of
an appointment with a physician 1 or more months ahead.
A pilot study from our group in which 45 patients dis-
charged from psychiatric hospital self-monitored symp-
toms using a daily computer-based self-monitoring system
emphasized the pivotal importance of continued contact
with a clinician such as a nurse [10]. Smartphones com-
prise a unique platform for the monitoring and treatment
of depression and mania. Depression and mania are associ-
ated with changes in several behavioral components (e.g.,
reduction in activity level, change in speech) and
motivational states (e.g., anhedonia), some of which may
be detectable using readily available smartphone sensors
[11–13]. Prior work done by our group has developed and
tested a unique smartphone-based system for the
treatment of bipolar disorder (the MONARCA system)
[14, 15]. The MONARCA system is capable of collecting
subjective self-assessment data and automatically generated
objective smartphone data from patients on a daily basis
while allowing simple bidirectional communication be-
tween clinicians and the patients [15]. We find it likely that
daily contact with a psychiatric hospital nurse using a
bidirectional feedback system combined with objective
smartphone-based early warning signs, assessed using a
smartphone app, will reduce the risk of re-admission and
the risk of relapse of depressive and (hypo)manic
symptoms.
Treatment of unipolar disorder and bipolar disorder
applies a variety of methods, including antidepressants,
mood stabilizers, psychoeducation, and cognitive behav-
ioral psychotherapy (CBT).
CBT has proven efficacious in the treatment and pre-
vention of depressive episodes in unipolar disorder [16],
but the effect in relation to bipolar disorder is controver-
sial [17]. Depressive symptoms dominate bipolar dis-
order as 80% of episodes are depressive [18], but bipolar
depression is difficult to treat as only a few drugs have
proven effects [19] and psychological interventions have
proven ambient effects on depressive symptoms reveal-
ing positive effects in some studies [20–22], but not in
others [23–25]. Specifically targeting depressive rumin-
ation, rumination-focused cognitive therapy and con-
creteness training (a facilitated self-help intervention
intended to increase specificity of processing in patients
with depression) have shown encouraging results in the
treatment of residual depression [26]. However, the
number of CBT therapists is very low compared with
the huge demand for CBT. Internet- and computer-
based CBT systems exist and have been proved effective
in relation to depression [27]. Recently, CBT has been
suggested for smartphones [28] but the effect has never
been tested in a randomized controlled trial (RCT).
In the RADMIS trial we will develop a smartphone-
based CBT program that includes methods to relieve de-
pressive ruminations [23, 29]. The smartphone-based
system used in the RADMIS trials is inspired by the
MONARCA system (see below), and is called the Mon-
senso system. By using the sensing, computational and
communication capabilities of smartphones, it is possible
to continuously monitor an individual’s context includ-
ing physical activity, location, and environment. Thus,
smartphones hold significant promise as a platform to
monitor behavioral and environmental indicators of de-
pression and mania and for treatment, facilitating early
intervention and smartphone-based CBT.
Prior research on using smartphones in the detection of
unipolar disorder and bipolar disorder has shown
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promising but preliminary results. A small study on eight
patients with depression (not including a control group)
found that sensor data from smartphones could detect so-
cial patterns [30]. Another study found that sensors from
smartphones were effective at detecting social and sleep
behaviors among patients with depression [31].
The MONARCA system, developed and tested by our
group [14, 15], has been proved highly usable and useful
by patients with bipolar disorder with a high self-
assessment adherence (87–95%), and was considered to
help patients to better manage their disease [32]. A study
investigating the effect of the MONARCA system (daily
self-monitoring including a two-level feedback loop to cli-
nicians) in a RCT found no overall effect in primary ana-
lyses but secondary analyses suggested that the system
was able to reduce manic symptoms, but may sustain de-
pressive symptoms in patients with bipolar disorder [33].
These results are in accordance with the findings that psy-
chological interventions for bipolar disorder in general
have more effect on manic than depressive symptoms and
more effect on preventing that treating acute depression
[23–25]. Consequently, emphasis on depressive symptoms
should be a high priority including considerations on
mechanisms to reduce the negative processing bias and
depressive ruminations in patients with unipolar disorder
and bipolar disorder [23, 33].
Finally, research by our group found that automatically
generated objective smartphone data reflect illness activ-
ity in patients with bipolar disorder. Data on physical ac-
tivity (the number of changes in cell tower ID/day),
social activity (the number and duration of phone calls/
day and the number of text messages/day) [11–13] and
voice features collected during phone calls [34] corre-
lated significantly with the severity of clinically rated de-
pressive and manic symptoms. Although these findings
are encouraging and innovative, there is a need to inte-
grate self-monitored smartphone data with automatically
generated objective smartphone data on physical and so-
cial activity, as well as speech and sleep, into a compos-
ite smartphone-generated electronic measure. This
composite measure should be modeled to have a high
correlation with depressive and manic symptoms, and a
high predictive ability to identify upcoming affective epi-
sodes for the individual patient in order to facilitate early
intervention.
Hypotheses
Using a smartphone-based monitoring and treatment sys-
tem for daily electronic self-monitoring, including an inte-
grated feedback loop, on both subjective and automatically
generated behavioral data on measures of illness activity
(phone usage, social activity, physical activity, mobility,
voice recognition and sleep) and context-aware CBT mod-
ules, the Monsenso system, reduces the rate and duration
of re-admission more than standard treatment in adult pa-
tients with unipolar disorder or bipolar disorder, respect-
ively, being discharged from hospital.
Objectives
To investigate in two individual, randomized controlled,
single-blind, parallel-group trials whether the use of a
smartphone-based monitoring and treatment system, in-
cluding an integrated feedback loop, on both subjective
and automatically generated behavioral data on mea-
sures of illness activity (phone usage, social activity,
physical activity, mobility, voice recognition and sleep)
and context-aware CBT modules, the Monsenso system,
reduces the rate and duration of re-admissions more
than treatment-as-usual in adult patients with unipolar
disorder or bipolar disorder, respectively.
Further, to investigate if the Monsenso system reduces the
severity of clinically rated affective symptoms and the num-
ber of affective episodes, improves psychosocial functioning,
quality of life, severity of self-assessed affective symptoms,
recovery, empowerment, adherence to medication, well-
being, and satisfaction with care, and reduces perceived
stress, rumination and worrying more than standard treat-
ment without a smartphone-based system in adult patients
with unipolar disorder or bipolar disorder, respectively.
Data will be collected and analyzed separately accord-
ing to psychiatric diagnosis (unipolar disorder and bipo-
lar disorder).
Methods
The present trial protocol is reported according to the
CONsolidated Standards Of Reporting Trials (CONSORT)
Statement and Standard Protocol Items: Recommenda-
tions for Interventional Trials (SPIRIT) [35–37] (Fig. 1,
Additional file 1).
The trial protocol describes two individual, random-
ized controlled, single-blind, parallel-group trials, the
RADMIS trials, investigating the effect of using the
Monsenso system on a daily basis, this including an inte-
grated feedback loop and context-aware CBT modules,
compared with standard treatment in adult patients with
unipolar disorder and bipolar disorder, respectively.
Trial design and study organization
The RADMIS trials are randomized controlled, single-
blind, parallel-group trials with a balanced allocation ratio
(1:1) of adult patients with unipolar disorder or bipolar dis-
order stratified according to the psychiatric center from
where the patients are discharged and the number of
former hospitalizations (three or less or more than three).
The included patients are randomized separately according
to psychiatric diagnosis (unipolar disorder or bipolar dis-
order) to either active use of the Monsenso system (inter-
vention group) or to standard treatment (control group).
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Thus, the RADMIS trials consists of two separate RCTs
with two patient groups investigating the effect of the same
intervention (the Monsenso system). The flow diagram of
the RADMIS trials is presented in Fig. 2. The trails are con-
ducted at the Psychiatric Center Copenhagen, Rigshospita-
let, Copenhagen, Denmark. No changes in study design or
methods have been made after trial commencement.
Participants and settings
Inclusion criteria: all patients over the age of 18 years
with a unipolar disorder or bipolar disorder diagnosis,
according to the International Classification of Diseases,
version 10 (ICD-10) using Schedules for Clinical Assess-
ments in Neuropsychiatry (SCAN) [38], who are dis-
charged from a psychiatric hospital in The Capital
Region of Denmark during the period March 2017 to
October 2018 following an affective episode (depression
or mania) are invited to participate in the RADMIS tri-
als. This corresponds to approximately 1200 patients
with unipolar disorder and 600 patients with bipolar dis-
order per year. The mental health services in The Cap-
ital Region of Denmark covers a recruitment area of the
Capital Region, Denmark, corresponding to 1.4 million
people.
Exclusion criteria: patients who are pregnant and those
who lack Danish language skills are excluded, since these
factors may influence the possible effect of the RADMIS
intervention.
Study procedure
Potential participants are invited to participate in the
RADMIS trials by contact with the staff during
hospitalization. All potential participants who accept to
meet with the RADMIS staff for further trial information
are screened by trained researcher to make sure that
they fulfil the criteria for participation, and are then in-
cluded in the RADMIS trials. Following inclusion, base-
line assessments are performed on all patients, and after
these assessments the numbered opaque allocation enve-
lopes are distributed by a research secretary (HGN) to
the RADMIS study nurses. The included patients are
randomized separately according to psychiatric diagnosis
(unipolar disorder or bipolar disorder) to either the
intervention group or the control group for a 6-month
trial period.
An overview of the outcome assessments conducted
by researchers blinded to intervention group is pre-
sented in Table 1. Information regarding the primary
outcome, re-admissions and duration of re-admissions,
will be obtained after completion of the two RCTs by
linkage of the unique personal identification number
(CPR) which is assigned to all 5.4 million persons living
in Denmark [39] with the Danish Psychiatric Central
Register [40].
The intervention group
All included patients have been discharged from a psy-
chiatric hospital at The Capital Region of Denmark dur-
ing the period from May 2017 to October 2018
following an affective episode (depression or mania). All
included patients continue standard treatment-as-usual
at a community psychiatric centre, a private psychiatrist,
a general practitioner or outpatient treatment at a hos-
pital during the trial period.
The smartphones
In the RADMIS trials, the Monsenso system is available
for smartphones capable of collecting subjective and
automatically generated behavioral data on measures of
illness activity. All patients randomized to the interven-
tion group are offered the loan of an Android smart-
phone free of charge for the 6-month trial period. The
patients in the intervention group are encouraged to use
the Monsenso system for daily electronic self-
monitoring. Economic costs from data traffic due to the
RADMIS trials are refunded to all participants regardless
the choice of smartphone type.
Subjective (self-monitored) measures of illness
activity in the intervention group The patients ran-
domized to the intervention group, regardless the choice
of smartphone are, on a daily basis, prompted by an alarm
in the Monsenso system at a self-chosen time during the
day to evaluate subjective measures of illness activity.
Fig. 1 Schedule of enrolment, interventions, and outcome assessments in the RADMIS trials
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Fig. 2 Flow diagram of the RADMIS trials
Table 1 Outcome assessments during the RADMIS trial
SCAN and background information Rating scales Questionnaires Clinical information
Baseline x x x x
Randomization to (1) smartphone-based monitoring and treatment (the intervention group) or (2) treatment-as-usual (the control group)
3-month follow-up x x x
6-month follow-up x x x
SCAN Schedules for Clinical Assessment in Neuropsychiatry interview
Rating scales: Hamilton Depression Rating Scale 17-item (HDRS-17); Young Mania Rating Scale (only for patients with a bipolar disorder diagnosis); Psychosocial
functioning test (Functional Assessment Short Test (FAST))
Questionnaires: perceived stress according to Cohen’s Perceived Stress Scale; quality of life according to the WHO Quality of Life-BREF (WHOQOL-BREF); self-rated
depressive symptoms according to Beck’s Depressive Inventory (BDI); self-rated depressive symptoms according to the Hamilton Depression Self-rating Scale
6-item (HDRS-6); self-rated manic symptoms according to the Altman Self-rating Scale for Mania (ASRM) (only for patients with a bipolar disorder diagnosis);
recovery according to the Recovery Assessment Scale; empowerment according to Rogers’ Empowerment Scale; adherence to medication according to the
Medicine Adherence Rating Scale; wellbeing according to the WHO (five) Wellbeing Index; rumination according to the Rumination Response Scale (RRS); worrying
according to the Penn State Worry Questionnaire (PSWQ); satisfaction according to the Verona Satisfaction Scale-Affective Disorder (VSS-A). The HDRS-6, the ASRM
and the WHO (five) are filled out every month during the study 6-month period
Clinical information: re-admissions and duration of re-admissions (register data); number of affective episodes; number of contacts with clinicians and psychiatric
emergency rooms; hospitalizations; medication, etc
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The following subjective (self-monitored) measures of ill-
ness activity are available for daily evaluation for patients
with unipolar disorder as well as bipolar disorder: sleep
duration (number of hours slept per night, measured in
half-hour intervals), time of falling asleep the previous
evening (hh:mm), time woken up the following morning
(hh:mm), medicine intake (taken as prescribed/taken with
changes (if changes, the patients are asked to specify
these)/not taken), anxiety (scored from “not present,”
“present to some degree” or “present” on a scale from 0, 1,
2), cognitive problems (scored from “not present,” “present
to some degree” or “present” on a scale from 0, 1, 2), alco-
hol consumption (number of units consumed per day, 0 to
+10 scale), stress (scored from “not present,” “present to
some degree” or “present” on a scale from 0, 1, 2), menstru-
ation for women (yes/no), individual early warning signs
(yes/no), a number (unlimited) of personal parameters (cre-
ated by the patients themselves), and a free-text note.
Suicidal thoughts will not be evaluated as part of the
self-monitoring due to ethical concerns and since deteri-
oration, leading to suicidal thoughts, will be reflected on
other of the self-monitored parameters in the system.
Suicidal patients will be treated using standard care and
taken care of by the usual clinician.
In addition to these items, the following self-monitored
measures of illness activity are available for daily evaluation
specifically for patients with unipolar disorder: mood
(scored from “euthymic” to “depressive” on a scale from 0,
−0.5, −1, −2, −3), activity level (scored from “normal” to
“very low” on a scale from 0, −1, −2, −3), irritability (scored
from “not present,” “present to some degree” or “present”
on a scale from 0, 1, 2). Similarly, the following additional
self-monitored measures of illness activity are available for
daily evaluation specifically for patients with bipolar dis-
order: mood (scored from “depressive” to “manic” on a
scale from −3, −2, −1, −0.5, 0, +0.5, +1, +2, +3), activity
level (scored from “very low” to “very high” on a scale from
−3, −2, −1, 0, +1, +2, +3), mixed mood (yes/no), irritability
(scored from “not present,” “present to some degree” or
“present” on a scale from 0, 1, 2).
After midnight, the entered subjective (self-monitored)
measures of illness activity are “locked” and further
changes cannot be made. If the patients wish to change
their subjective evaluation they can enter a second
evaluation in addition to the initial one, and both of the
subjective evaluations are then visible for the patient and
the health care provider when logging on to in the Mon-
senso system. If the patients forget to evaluate the sub-
jective measures it is possible to enter and evaluate
retrospectively for up to 2 days. It is then noted in the
Monsenso system that the subjective measures are col-
lected retrospectively. Screenshots from the Monsenso
system are presented in Figs. 3 and 4. A user’s guide for
the Monsenso system was developed and handed out to
all patients in the intervention group (can be obtained
by contacting the corresponding author).
Automatically generated behavioral data (objective
data) on measures of illness activity Smartphones are
capable of collecting automatically generated behavioral
data on measures of illness activity on a daily basis (ob-
jective data) during the 6-month trial period.
Examples of some of the automatically generated be-
havioral data on measures of illness activity collected by
the smartphones: (1) phone usage measured as the num-
ber of times and amount of time the smartphones screen
are turned on/off, battery usage, ambient light, and
“proximity” detection, (2) social activity measured as the
number of in- and outgoing phone calls and text mes-
sages, the duration of in- and outgoing phone calls, the
length of the text messages, and the time of the day
when the phone calls and/or text messages are made/
Fig. 3 The Monsenso self-assessment system. Screenshot of the
smartphone-based self-assessment
Fig. 4 The Monsenso self-assessment system. Screenshot of the
smartphone-based self-assessment of mood
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sent/received, (3) physical activity measured by the step
counter in the smartphones, and (4) mobility based on
the location estimation available in the smartphones
(which again rely on, e.g., GPD or GSM cell tower infor-
mation depending on specific circumstances). Further-
more, speech activity is collected by extraction of
different voice features during phone calls. Voice feature
extraction will take place directly on the smartphones
and no recording of the actual speech/conversation will
take place. The intention is to synthesize these automat-
ically generated behavioral data into one aggregated ob-
jective composite measure.
Smartphone-based CBT modules The smartphone-
based CBT modules include four modules: psychoeduca-
tion, behavioral activation, cognitive restructuring and
rumination-focused CBT. The psychoeducation and
mood-monitoring system include strategies for detecting
and intervening with early signs of relapse. Patients are
encouraged to use the module in an individualized and
sequential way according to their condition, affective
state, and insight and following guidance from the study
nurse if wanted. The behavioral activation module was
inspired by Martell et al. (2010) and Lejuez et al. (2001)
[41, 42]. It includes activity monitoring and activity
scheduling and focus on regulation of sleep and daily
routines. Several studies have established the efficacy for
behavioral activation for treating depression [43–46] in-
cluding a few studies of behavioral activation using
smartphones; however, not including a control standard
treatment arm [47, 48]. Further, regulating patterns of
activity and sleep are helpful in reducing both depressive
and manic symptoms [43, 49].
The cognitive restructuring includes simple techniques to
help patients to identify and modify dysfunctional auto-
matic thoughts. Cognitive restructuring is a key element of
CBT and is included in a number of studies that show the
efficiency of CBT in the treatment of depression including
some studies of Internet-based CBT [50, 51], and a few
studies including patients with bipolar disorder [20, 22].
A main purpose of the smartphone-based CBT modules
was to help patients to reduce depressive ruminations.
Therefore, a specific rumination-focused CBT strategy,
based on the theory and practice described by Watkins et
al. [25], was included. Rumination-focused CBT has
shown encouraging results in the treatment of residual de-
pression [25] and the Monsenso system includes the iden-
tification and reduction of unhelpful ruminations.
The integrated feedback loop between patients and
clinicians Study nurses with experience with unipolar
disorder and bipolar disorder are assigned to the pa-
tients allocated to the intervention group of the RAD-
MIS trials. The RADMIS study nurses are responsible
for the integrated feedback loop. Patients allocated to
the intervention group of the RADMIS trials will have
the Monsenso application installed on a smartphone.
The smartphone automatically transfers the self-
monitored subjective measures and, for some smart-
phones, also the automatically generated behavioral
data on measures of illness activity to servers at the
hospital through secure connections (I-suite number
RHP-2011-03). By giving informed consent to partici-
pate in the RADMIS, the patients allow for the RAD-
MIS study nurses and their health care provider to
access the monitored data through a secure web
interface. The RADMIS study nurses go through the
collected data approximately two to three times a
week, or more often on patients where it is deemed
necessary. A personal homepage is set up on a server
allowing the patients to access all their own data
through a similar secure web interface.
1. The feedback loop on subjective measures:
regardless the type of smartphone a feedback loop
on the subjective measures is established. A
standard of scoring thresholds for when the
RADMIS study nurses initially should react was
made. For example, the RADMIS study nurses
react if the patients register ≥ −2 on the mood
item for 2 days or more, or if the patients
register changes in their sleep patterns of 1 h or
more for more than 3 days. Following a run-in
phase of approximately 2 to 4 weeks of self-
monitoring, the patients and the RADMIS study
nurses individualize the thresholds for when reac-
tion should be made. Also the RADMIS study
nurses and the patients agree on a concordance
status in (a) the patients’ most important items
for identifying prodromal symptoms of depression
as well as (hypo)mania (only for patients with a
bipolar disorder diagnosis), (b) the threshold for
future early warning signs, and (c) actions to be
taken in case of depression or (hypo)mania (only
for patients with a bipolar disorder diagnosis)
2. The integrated feedback loop on subjective and
automatically generated behavioral data on
measures of illness activity: a feedback loop
integrating subjective and automatically generated
behavioral data on measures of illness activity is
established. The feedback loop integrates both
subjective and automatically generated behavioral
data on measures of illness activity in a flexible
and adjustable model (a learning system) resulting
in prediction analyses of the collected data
providing messages for both the patients and the
RADMIS study nurses such as: “You are invited
to contact your RADMIS study nurse.”
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Actions taken by the RADMIS study nurses, as part of
the feedback loop in the intervention group, in case of signs
of deterioration of a patient in the intervention group:
1. Contact the patient and give advice on how to
handle the situation
2. If the first action is not enough, the study nurses
ask the patient to contact the usual physician or
other clinician
3. If the above actions are not enough, or if contact
with the patient is not possible, the study nurses
contact the patient’s usual physician or other
clinician themselves
4. In case of acute deterioration and/or severe
symptoms, the study nurses recommend the patient
to contact the psychiatric emergency service in
Copenhagen, Denmark
The Monsenso system was designed in an interactive
process between patients with unipolar disorder, bipolar
disorder, IT researchers, clinicians, and clinical re-
searchers before the beginning of the RADMIS trial.
The control group
Patients allocated to the control group continue with
their standard treatment-as-usual and are asked to con-
tinue communicating as usual using their mobile phone
(smartphone).
Assessments
Researchers blinded to the patients’ allocation of interven-
tion group (MFJ and one other physician) who are not in-
volved in the treatment of the patients carry out all
outcome assessments. The unipolar disorder or bipolar
disorder diagnoses according to ICD-10 are confirmed by
a SCAN interview before inclusion of the patients. The
patients are, regardless of randomization group, enrolled
for a 6-month trial period and invited for outcome assess-
ments by researchers blinded to intervention at baseline,
after 3 months and after 6 months (Table 1).
At each visit with the researchers, the assessments in-
clude the following:
1. Clinician-administrated rating scales: the severity of
depressive and manic symptoms (manic symptoms only
assessed for patients with a bipolar disorder diagnosis) is
measured using the Hamilton Depression Rating Scale
17-item (HDRS-17) [52] and the Young Mania Rating
Scale (YMRS) [34], respectively, and psychosocial func-
tioning is measured using the Functioning Assessment
Short Test (FAST) [53]
2. Questionnaires: perceived stress according to
Cohen’s Perceived Stress Scale [54], quality of life ac-
cording to the WHO Quality of Life-BREF (WHOQOL-
BREF) [55], self-rated depressive symptoms according to
Beck’s Depressive Inventory (BDI) [56–58], self-rated de-
pressive symptoms according to the Hamilton Depres-
sion Self-rating Scale 6-item (HDRS-6) [59], self-rated
manic symptoms according to Altman Self-rating Scale
for Mania (ASRM) (only for patients with a bipolar dis-
order diagnosis) [34], recovery according to the Recovery
Assessment Scale [60], empowerment according to Rog-
ers’ Empowerment Scale [61], adherence to medication
according to the Medicine Adherence Rating Scale [62],
wellbeing according to the WHO (five) Wellbeing Index
[63], rumination according to the Ruminative Response
Scale (RRS), worrying according to the Penn State
Worry Questionnaire (PSWQ) [64], and satisfaction ac-
cording to the Verona Satisfaction Scale-Affective Dis-
order (VSS-A) [65]. The patients are asked to fill out
HDRS-6, ASRM (only for patients with a bipolar diagno-
sis) and WHO (five) every month during the 6-month
trial period in both groups and in both trials.
Outcomes
Primary outcomes
 Rate and duration of hospital re-admissions of
patients with unipolar disorder and bipolar disorder,
respectively, as according to data retrieved from the
Danish Psychiatric Central Register [40]
Secondary outcomes
 Severity of depressive symptoms and manic
symptoms (manic symptoms only for patients with a
bipolar disorder diagnosis) measured using the
HDRS-17 and the YMRS, respectively
 Psychosocial functioning according to the
Functional Assessment Short Test (FAST)
 Number of depressive episodes and manic episodes
(manic episodes only for patients with a bipolar
disorder diagnosis) defined as HDRS-17 > 13 and
YMRS >13, respectively
 Automatically generated behavioral data measured
as an aggregated composite measure
Tertiary outcomes
 Perceived stress according to Cohen’s Perceived
Stress Scale [54], quality of life according to the
WHO Quality of Life-BREF (WHOQOL-BREF) [55],
self-rated depressive symptoms according to Beck’s
Depressive Inventory (BDI) [56–60], self-rated
depressive symptoms according to the Hamilton
Depression Self-rating Scale 6-item (HDRS-6) [59],
self-rated manic symptoms according to the Altman
Self-rating scale for Mania (ASRM) (only for
patients with a bipolar disorder diagnosis) [34],
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recovery according to the Recovery Assessment
Scale [60], empowerment according to Roger’s
Empowerment Scale [61], adherence to medication
according to the Medicine Adherence Rating Scale
[62], wellbeing according to the WHO (five) Well-
being Index [63], rumination according to the
Ruminative Response Scale (RRS), worrying according
to the Penn State Worry Questionnaire (PSWQ) [64],
and satisfaction according to the Verona Satisfaction
Scale-Affective Disorder (VSS-A) [65]
No changes in trial outcomes have been made after
trial commencement.
Statistical power and sample size calculation
The statistical power and sample size was calculated
using http://stat.ubc.ca/~rollin/stats/ssize/n2.html.
The primary outcomes are differences in the number
and duration of re-admissions to a psychiatric hospital be-
tween the intervention group and the control group − ana-
lyzed separately according to psychiatric diagnosis
(unipolar disorder or bipolar disorder). Power calculations
are similar for the two RCTs/patient groups (unipolar dis-
order or bipolar disorder). Based on prior findings aiming
to reduce re-hospitalization due to recurrent depression
[66] and bipolar disorder [9], combined with presump-
tions of positive effects of the immediate early contact
with patients during the vulnerable period following dis-
charge from a psychiatric hospital, regardless of diagnosis,
we expect a reduction in re-admissions from 30% to 15%
in the intervention group using smartphone-based treat-
ment. Thus, anticipating a hazard ratio (HR) of 0.50 in the
comparison of the intervention group with the control
group on the primary outcome, a two-sided risk of type 1
error, α of 0.05, a type 2 error risk, β, a statistical power of
80%, the sample size (N) is calculated as N = 200 (100 pa-
tients in each arm of each RCT) per RCT and, thus, a total
of 400 patients (200 patients with unipolar disorder and
200 patients with bipolar disorder) is estimated to be re-
quired for the RADMIS trial. Cumulated durations of re-
hospitalizations comprise similar power calculations and
sample sizes. Regarding the secondary outcomes, the clin-
ically relevant difference in depressive or manic symptoms
is defined as a minimum of three scores on the HDRS-17
or on the YMRS, respectively, and the standard deviation
(SD) is set at 7 with a mean score of 12 versus 15 in the
intervention group and the control group, respectively.
The statistical power to detect a three-score difference in
the areas under the curves between the intervention and
the control groups on the HDRS-17 or the YMRS, re-
spectively, is 80% with α = 0.05 for a two-sample compari-
son of means including a total of 200 patients (100
patients in each arm) in each of the two RADMIS RCTs.
Randomization
Sequence generation
A computer-generated list of random allocation num-
bers using Pharma Consulting Group (http://www.phar-
maconsultinggroup.com) will be generated. Patients
included in the trial are randomized with a balanced al-
location ratio of 1:1 to (1) using the Monsenso system,
including the integrated feedback loop, based on a com-
bination of subjective self-monitored measures and auto-
matically generated behavioral data on measures of
illness activity) including context-aware CBT modules
(the intervention group) or to (2) standard treatment-as-
usual (the control group) (Fig. 1).
Since the RADMIS trial is single-blinded, random
block sizes are used to help preserve unpredictability
[67, 68]. The RADMIS study nurses are unaware of the
range of numbers in the block sizes.
The study will use a stratified design, where patients
are stratified according to the psychiatric centres where
patients are discharged from and according to the num-
ber of previous hospitalizations (three or less or more
than three). The statistical analyses will adjusted for the
two stratification variables, and also age and sex as pos-
sible prognostic variables. Further, in analyses on con-
tinuous variables, potential differences in baseline score
on the outcome in question will be included as a poten-
tial confounder. If there are no statistically significant
main effects of age and sex, these variables will be ex-
cluded from the final statistical analyses.
Allocation concealment and implementation
The allocation sequence is concealed from the re-
searchers (e.g., MFJ) enrolling and assessing the patients
and from the RADMIS study nurses. Allocation is con-
cealed in numbered, opaque and sealed envelopes.
Blinding
Owing to the type of intervention in the RADMIS trials,
the patient, the patients’ health care provider and the
RADMIS study nurses are aware of the allocated
randomization group. The researchers responsible for
outcome assessments, data entry, data analyses, inter-
pretation of analyses and writing of papers are kept
blinded to allocation at all times during the trial period,
data analyses and interpretation of analyses. The trials
are, therefore, single-blinded. The RADMIS study nurses
do not collect any outcome measures. At each visit with
the researchers, all patients are thoroughly instructed
not to mention anything about randomization allocation.
In case of unblinding of the included patients’ allocation
status, one of the other researchers blinded to interven-
tion in the RADMIS trials will conduct the outcome
assessments.
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Statistical methods
Data from all randomized patients are collected until drop-
out or the end of the trial period. Analysis will be carried
out with an intention-to-treat (ITT) approach. The primary
outcomes are differences in time to re-admission and dur-
ation of re-admissions during the 6-month trial period be-
tween the intervention group and the control group. Time
to the first re-admission will be estimated using a Kaplan-
Meier plot with reasons for censoring being date of death
or end of study. The differences in cumulated prevention of
re-admission in the intervention group and the control
group will tested using a log-rank test. Analysis of second-
ary and tertiary outcomes will be done employing a linear
mixed-effects model with random intercept for each par-
ticipant and a fixed effect of visit. Differences in outcomes
between the intervention group and the control group will
be analyzed, firstly in an unadjusted model (except for dif-
ferences in baseline values of the outcome variable in ana-
lyses on continuous variables) and then in models adjusted
for the two stratification variables (1) psychiatric center and
(2) the number of prior hospitalizations, and also for age
and sex as possible prognostic variables. If there are no sta-
tistically significant main effects of age and sex, these vari-
ables will be excluded from the final analyses. Furthermore,
subanalyses will be done employing a linear mixed-effects
model with random intercept for each participant and a
fixed effect of visit on differences in the HDRS-17 and the
YMRS in patients with the presence of depressive and
manic symptoms (defined as HDRS-17 > 0 or YMRS >0, re-
spectively) at a given time point during the trial period be-
tween the intervention group and the control group.
Additionally, in addition to analyses of the secondary out-
comes, we will analyze differences in depressive and manic
episodes defined as HDRS ≥14 and YMRS ≥14, respectively,
during the trial period. Potential interactions between
randomization group and visit number on any specific out-
come variable in the analyses will be investigated and re-
ported accordingly. The statistical threshold for significance
is p ≤ 0.05 (two-tailed). Data will be managed by MFJ and
entered using Epidata®. All analyses will be done using
SPSS, version 22.0 (IBM, New York, NY, USA) and STATA
version 12 (StataCorp LP, College Station, TX, USA).
Discussion
Monitoring of illness activity using smartphones seems
promising as an intervention in unipolar disorder and
bipolar disorder, but few studies using rigorous method-
ology have been published. No study investigating the ef-
fect of a smartphone-based intervention on rate and
duration of re-admissions in both unipolar disorder and
bipolar disorder has been published. The RADMIS trials
aim to investigate the effect of a smartphone-based
monitoring and treatment system on the risk of psychi-
atric hospitalization, clinical function, and wellbeing in
randomized, controlled trials with clearly defined clinical
outcome measures.
Advantages
First, the RADMIS trials’ use a pragmatic design with few
exclusion criteria and the results of the trials will be
generalizable to patients who are going to be discharged
from psychiatric hospitals in general with a diagnosis of
unipolar disorder or bipolar disorder and have clinical rele-
vance. The patients are recruited at a critical time point at
discharge from hospital at which they still suffer from some
affective symptoms and have a need for continued treat-
ment. Following hospitalization, patients often experience a
service gap between inpatient and outpatient services, and
the RADMIS smartphone-based monitoring and treatment
system is developed among others to fill out this gap.
Second, it is a major advantage that clinical information
on the primary outcome will be available for all included
patients (100%), regardless of whether they drop out of
the RADMIS trials or not, as data on date of re-admission
and duration of re-hospitalizations routinely are reported
nationwide to the Danish Psychiatric Central Register
[40]. Also, the information on re-admissions and duration
of re-hospitalizations are collected without the risk of
unblinding of the researcher and not based on the pa-
tients’ subjective evaluations.
Third, information on the secondary outcome mea-
sures are based on standardized clinical rating scales
often used as the “gold standard,” and are conducted by
trained researchers blinded to intervention groups. In
contrast to this, the tertiary outcomes are based on the
patients’ subjective and unblinded evaluations and are,
thus, at risk of performance bias.
Fourth, the intervention used in the RADMIS trials is
specifically designed to address the needs of the patients
when being discharged from a psychiatric hospitalization.
During the design phase of the trial the software was
designed in a close collaboration between patients with uni-
polar disorder and bipolar disorder, IT researchers, clini-
cians, and clinical researchers during an interactive process.
Fifth, automatically generated behavioral data collected
by the smartphones will be combined in an aggregated
combined measure of illness activity that will be reported
as an additional outcome measure. These data are object-
ive and have been shown to correlate with the severity of
depressive and manic symptoms in studies by our group.
However, using these data as outcome measures is still ex-
perimental and will be developed further during the RAD-
MIS trials. Consequently, the aggregated smartphone-
based measure of illness activity is not included as a pre-
defined outcome measure in this study protocol.
Sixth, the Monsenso system will be available for both
Android and iPhones. Thus, patients are not excluded
due to preference of smartphone type and/or operating
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system. Patients randomized to the intervention group
are offered to loan a smartphone free of charge during
the RADMIS trials and, thus, there are no requirements
for smartphone access.
Limitations
The intervention group
The RADMIS trials are designed to investigate the effect
of the entire Monsenso system, including self-monitoring,
automatically generated behavioral data, integrated feed-
back loop and context-aware CBT modules. Thus, we will
not be able to distinguish the effects of the individual
components of the intervention.
However, in subanalyses it will be investigated whether
there are differences in outcome measures between pa-
tients who have used the CBT modules during the trial
period and patients who have not.
The control group
It is always difficult to define a proper control group. In
a previously trial conducted by the authors, an effect of
a “placebo smartphone” was most likely not found [32].
Further, during the last years few of the patients partici-
pating in our studies have expressed a wish to loan a
smartphone free of charge. Thus, we chose not to offer a
placebo smartphone in the present RADMIS trial.
Secondary and tertiary outcome measures
The secondary outcome measures are differences in clinic-
ally rated depressive and manic symptoms as assessed with
standardized rating scales. Since the patients are aware of
their allocation status these outcome measures are single
blinded. The tertiary outcomes are questionnaires evaluated
by the patients themselves and are, therefore, unblinded.
Perspectives
If the Monsenso system proves effective in reducing the
rate and duration of re-admissions in patients with uni-
polar disorder and bipolar disorder in the present trial,
there will be basis for using a system of this kind in psy-
chiatric treatment in general and on a larger scale.
Trial status
The trial is ongoing. Recruitment begins March 2017.
Additional file
Additional file 1: SPIRIT checklist for the RADMIS trial. (DOC 115 kb)
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